Polyplus-Transfection SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Polyplus-Transfection SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014196
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Polyplus-Transfection SA (Polyplus) is a biotechnology company that develops and markets solutions for in vivo and in vitro delivery of nucleic acids in research, bioproduction and therapeutics. The company develops its RNA interference such as STICKY SIRNA and SIRNAPLUS for invivo research. Polyplus also develops transfection reagents which include JetPRIME, JetPEI, PEIpro, INTERFERin, PULSin and ZNA among others. Polyplus also provides reagents for preclinical and clinical trials. The company’s products find application in gene expression, RNA interference, protein production, in vivo delivery, virus production, molecular biology and diagnostics and protein delivery. It markets its wide range of transfection reagents through a global distributor network. Polyplus is headquartered in Strasbourg, France.

Polyplus-Transfection SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Polyplus-Transfection SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Polyplus-Transfection SA, Medical Devices Deals, 2011 to YTD 2017 8
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Polyplus-transfection Enters into Licensing Agreeement with Blue Sky BioServices 10
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 11
Polyplus-transfection Enters Into Licensing Agreement With Merck 12
Polyplus-transfection Enters Into Licensing Agreement With Roche Glycart 13
Polyplus-Transfection SA – Key Competitors 14
Polyplus-Transfection SA – Key Employees 15
Polyplus-Transfection SA – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Key Facts 2
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Polyplus-Transfection SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Polyplus-Transfection SA, Medical Devices Deals, 2011 to YTD 2017 8
Polyplus-Transfection SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Polyplus-transfection Enters into Licensing Agreeement with Blue Sky BioServices 10
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 11
Polyplus-transfection Enters Into Licensing Agreement With Merck 12
Polyplus-transfection Enters Into Licensing Agreement With Roche Glycart 13
Polyplus-Transfection SA, Key Competitors 14
Polyplus-Transfection SA, Key Employees 15
Polyplus-Transfection SA, Other Locations 16

★海外企業調査レポート[Polyplus-Transfection SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enstar Group Ltd.:企業の戦略・SWOT・財務情報
    Enstar Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Enstar Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Universal Corporation:企業の戦略・SWOT・財務分析
    Universal Corporation - Strategy, SWOT and Corporate Finance Report Summary Universal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Shinsung Solar Energy Co Ltd (011930)-エネルギー分野:企業M&A・提携分析
    Summary Shinsung Solar Energy Co., Ltd. (Shinsung Solar) is a provider of solar cells. Its products include single-crystalline and multi-crystalline solar cells, and mono-crystalline and multi-crystalline solar panels. Through its subsidiaries, the company offers installment financing, lease financi …
  • Big Rivers Electric Corporation:企業の発電所・SWOT分析2018
    Big Rivers Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Quadra – Power Generation (TGKD):企業の財務・戦略的SWOT分析
    Quadra - Power Generation (TGKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ceres Power Holdings Plc (CWR):電力:M&Aディール及び事業提携情報
    Summary Ceres Power Holdings Plc (Ceres Power) is an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power and heat …
  • ProMIS Neurosciences Inc (PMN):企業の製品パイプライン分析
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of neurodegenerative disorders. Its major products include tests functional assa …
  • Arkansas Electric Cooperative Corporation:企業の戦略的SWOT分析
    Arkansas Electric Cooperative Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …
  • Becton Dickinson and Co (BDX):企業の財務・戦略的SWOT分析
    Becton Dickinson and Co (BDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cardia Inc-医療機器分野:企業M&A・提携分析
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures, and markets transcatheter septal occluders for cardiac defect patients. The company’s products include ultrasept ASD, ultraseptLAA, ultraseptPFO, fontan occlude among others. Its UltraseptASD is used for the transven …
  • Isagen SA ESP:企業の発電所・SWOT分析2018
    Isagen SA ESP - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • DURECT Corp (DRRX):企業の財務・戦略的SWOT分析
    DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • LivaNova PLC (LIVN):企業の財務・戦略的SWOT分析
    LivaNova PLC (LIVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Applied Materials Inc (AMAT):企業の財務・戦略的SWOT分析
    Applied Materials Inc (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vigor Shipyards, Inc:企業の戦略・SWOT・財務分析
    Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report Summary Vigor Shipyards, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Michael Hill International Ltd (MHJ):企業の財務・戦略的SWOT分析
    Michael Hill International Ltd (MHJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Zosano Pharma Corp (ZSAN):企業の財務・戦略的SWOT分析
    Summary Zosano Pharma Corp (Zosano Pharma), formerly ZP Holdings Inc, is a clinical stage biopharmaceutical company that develops proprietary transdermal delivery system. The company develops a transdermal microneedle patch system to deliver its drug formulations through the skin for the treatment o …
  • Siltech Corp:企業の戦略的SWOT分析
    Siltech Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Meketa Investment Group:企業の戦略・SWOT・財務分析
    Meketa Investment Group - Strategy, SWOT and Corporate Finance Report Summary Meketa Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆